Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VABu Conditioning Regimen in Elderly AML Patients Undergoing HSCT
NCT07583888Phase 3Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2026
- Primary completion
- Aug 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of venetoclax, azacitidine, semustine, cytarabine and busulfan in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Progression-Free Survival at 2 years. Started May 2026; status: recruiting.
02
Drugs
venetoclaxazacitidinesemustinecytarabinebusulfan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07583888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583888.